To determine whether ADAMTS16 mutations affect cell viability, we first analyzed ovarian cancer cells that stably expressed EV, or one of six ADAMTS16 missense mutants (C274R, F660I, S787Y, A1155V, S1170L, or K1206M) using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay over a period of 6 days (Figure 2A solid lines). This evidence concerns the gene ADAMTS16 and ovarian cancer.